Phase 2 N=40 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Multiple Myeloma
Primary: Efficacy of BCMA CAR-T Cell Therapy — 25; 13 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Kidney Disease, Chronic
Primary: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 — 48.9; 16.0; 38.5; 11.4 Predicted percentage of…
N/A N=20 COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial
COVID-19
Primary: Mean Fidelity Score — 18.1; 18.4 score on a scale
Phase 3 N=41 Study of Ravulizumab in Pediatric Participants With HSCT-TMA
Thrombotic Microangiopathy
Primary: Participants With Thrombotic Microangiopathy (TMA) Response — 7 Participants
N/A N=445 Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
Covid19 and Mortality
Primary: Acute Physiology and Chronic Health Evaluation II Score — 13.1; 18.3 score on a scale
N/A N=760 Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
SARS-CoV-2 · COVID-19
Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants
N/A N=4,779 Palliative Care Educator
Advance Care Planning · Palliative Care · Alzheimer's Disease and Related Dementias
Primary: Identification of a Goals of Care Conversation in the Electronic Health Record (EHR) During the Index Hospitalization — 3744; 2396 Participants
Phase 2 N=83 Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
Stroke, Ischemic
Primary: Number of Participants With Serious Adverse Events (SAEs) — 6; 10; 8 Participants
Phase 2 N=101 Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT — -0.47; -3.32 mg/cm^3
N/A N=187 Modifiable Predictors of Neural Vulnerabilities for Obesity
Obesity
Primary: Caudate Activation for Sip Cue — -0.026264341 activation beta value
Phase 3 N=119 A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
Pompe Disease (Late-onset)
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug — 80; 37…
Phase 2 N=251 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Ebola
Primary: Number of Participants With Solicited Adverse Events Following V920 Vaccination — 5; 1; 2; 1 Participants
Phase 3 N=340 LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 2.86; 2.56 Months — p=0.0005
N/A N=131,005 A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
COVID-19 (Coronavirus Disease 2019)
Primary: Number of Participants According to Age Group: Unmatched Participants — 57; 686; 545; 6123 Participants
N/A N=69 Clareon PanOptix Pro vs. Clareon PanOptix - Study B
Aphakia · Presbyopia
Primary: Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) — -0.016; 0.010 logMAR